Cargando…
The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset
PURPOSE: To explore the effect of erdosteine on COPD exacerbations, health-related quality of life (HRQoL), and subjectively assessed COPD severity. PATIENTS AND METHODS: This post-hoc analysis of the RESTORE study included participants with COPD and spirometrically moderate (GOLD 2; post-bronchodil...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416404/ https://www.ncbi.nlm.nih.gov/pubmed/36034589 http://dx.doi.org/10.2147/COPD.S369804 |
_version_ | 1784776472152506368 |
---|---|
author | Calverley, Peter M A Papi, Alberto Page, Clive Rogliani, Paola Dal Negro, Roberto W Cazzola, Mario Cicero, Arrigo F Wedzicha, Jadwiga A |
author_facet | Calverley, Peter M A Papi, Alberto Page, Clive Rogliani, Paola Dal Negro, Roberto W Cazzola, Mario Cicero, Arrigo F Wedzicha, Jadwiga A |
author_sort | Calverley, Peter M A |
collection | PubMed |
description | PURPOSE: To explore the effect of erdosteine on COPD exacerbations, health-related quality of life (HRQoL), and subjectively assessed COPD severity. PATIENTS AND METHODS: This post-hoc analysis of the RESTORE study included participants with COPD and spirometrically moderate (GOLD 2; post-bronchodilator forced expiratory volume in 1 second [FEV(1)] 50‒79% predicted; n = 254), or severe airflow limitation (GOLD 3; post-bronchodilator FEV(1) 30‒49% predicted; n = 191) who received erdosteine 300 mg twice daily or placebo added to usual maintenance therapy for 12 months. Antibiotic and oral corticosteroid use was determined together with patient-reported HRQoL (St George’s Respiratory Questionnaire, SGRQ). Patient and physician subjective COPD severity scores (scale 0‒4) were rated at baseline, 6 and 12 months. Data were analyzed using descriptive statistics for exacerbation severity, COPD severity, and treatment group. Comparisons between treatment groups used Student’s t-tests or ANCOVA as appropriate. RESULTS: Among GOLD 2 patients, 43 of 126 erdosteine-treated patients exacerbated (7 moderate-to-severe exacerbations), compared to 62 of 128 placebo-treated patients (14 moderate-to-severe exacerbations). Among those with moderate-to-severe exacerbations, erdosteine-treated patients had a shorter mean duration of corticosteroid treatment (11.4 days vs 13.3 days for placebo, P = 0.043), and fewer patients required antibiotic treatment with/without oral corticosteroids (71.4% vs 85.8% for placebo, P < 0.001). Erdosteine-treated GOLD 2 patients who exacerbated showed significant improvements from baseline in SGRQ total scores and subjective disease severity scores (patient- and physician-rated), compared with placebo-treated patients regardless of exacerbation severity. Among GOLD 3 patients, there were no significant differences between treatment groups on any of these measures. CONCLUSION: Adding erdosteine to the usual maintenance therapy of COPD patients with moderate airflow limitation reduced the number of exacerbations, the duration of treatment with corticosteroids and the episodes requiring treatment with antibiotics. Additionally, treatment with erdosteine improved HRQoL and patient-reported disease severity. |
format | Online Article Text |
id | pubmed-9416404 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-94164042022-08-27 The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset Calverley, Peter M A Papi, Alberto Page, Clive Rogliani, Paola Dal Negro, Roberto W Cazzola, Mario Cicero, Arrigo F Wedzicha, Jadwiga A Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: To explore the effect of erdosteine on COPD exacerbations, health-related quality of life (HRQoL), and subjectively assessed COPD severity. PATIENTS AND METHODS: This post-hoc analysis of the RESTORE study included participants with COPD and spirometrically moderate (GOLD 2; post-bronchodilator forced expiratory volume in 1 second [FEV(1)] 50‒79% predicted; n = 254), or severe airflow limitation (GOLD 3; post-bronchodilator FEV(1) 30‒49% predicted; n = 191) who received erdosteine 300 mg twice daily or placebo added to usual maintenance therapy for 12 months. Antibiotic and oral corticosteroid use was determined together with patient-reported HRQoL (St George’s Respiratory Questionnaire, SGRQ). Patient and physician subjective COPD severity scores (scale 0‒4) were rated at baseline, 6 and 12 months. Data were analyzed using descriptive statistics for exacerbation severity, COPD severity, and treatment group. Comparisons between treatment groups used Student’s t-tests or ANCOVA as appropriate. RESULTS: Among GOLD 2 patients, 43 of 126 erdosteine-treated patients exacerbated (7 moderate-to-severe exacerbations), compared to 62 of 128 placebo-treated patients (14 moderate-to-severe exacerbations). Among those with moderate-to-severe exacerbations, erdosteine-treated patients had a shorter mean duration of corticosteroid treatment (11.4 days vs 13.3 days for placebo, P = 0.043), and fewer patients required antibiotic treatment with/without oral corticosteroids (71.4% vs 85.8% for placebo, P < 0.001). Erdosteine-treated GOLD 2 patients who exacerbated showed significant improvements from baseline in SGRQ total scores and subjective disease severity scores (patient- and physician-rated), compared with placebo-treated patients regardless of exacerbation severity. Among GOLD 3 patients, there were no significant differences between treatment groups on any of these measures. CONCLUSION: Adding erdosteine to the usual maintenance therapy of COPD patients with moderate airflow limitation reduced the number of exacerbations, the duration of treatment with corticosteroids and the episodes requiring treatment with antibiotics. Additionally, treatment with erdosteine improved HRQoL and patient-reported disease severity. Dove 2022-08-22 /pmc/articles/PMC9416404/ /pubmed/36034589 http://dx.doi.org/10.2147/COPD.S369804 Text en © 2022 Calverley et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Calverley, Peter M A Papi, Alberto Page, Clive Rogliani, Paola Dal Negro, Roberto W Cazzola, Mario Cicero, Arrigo F Wedzicha, Jadwiga A The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset |
title | The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset |
title_full | The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset |
title_fullStr | The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset |
title_full_unstemmed | The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset |
title_short | The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset |
title_sort | effect of maintenance treatment with erdosteine on exacerbation treatment and health status in patients with copd: a post-hoc analysis of the restore dataset |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416404/ https://www.ncbi.nlm.nih.gov/pubmed/36034589 http://dx.doi.org/10.2147/COPD.S369804 |
work_keys_str_mv | AT calverleypeterma theeffectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT papialberto theeffectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT pageclive theeffectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT roglianipaola theeffectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT dalnegrorobertow theeffectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT cazzolamario theeffectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT ciceroarrigof theeffectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT wedzichajadwigaa theeffectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT calverleypeterma effectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT papialberto effectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT pageclive effectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT roglianipaola effectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT dalnegrorobertow effectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT cazzolamario effectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT ciceroarrigof effectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset AT wedzichajadwigaa effectofmaintenancetreatmentwitherdosteineonexacerbationtreatmentandhealthstatusinpatientswithcopdaposthocanalysisoftherestoredataset |